Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs

Annals of the Rheumatic Diseases

Volumn 65, Issue 1, 2006, Pages 7-13

  Bolten, W W ^a  

^a Klaus Miehlke Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ATHEROGENESIS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; DIGESTIVE SYSTEM PERFORATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; LUNG EMBOLISM; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SKIN MANIFESTATION; STROKE; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATHEROSCLEROSIS; BLOOD PLATELETS; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; THROMBOSIS; THROMBOXANE A2;

EID: 29144483297     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.036269     Document Type: Review

References (45)

1. Ross R. Atherosclerosis-an Inflammatory disease. N Engl J Med 1999;340:115-26.
2. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002;89:26-32D.
3. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-9.
4. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004;306:1954-7.
5. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-41.
6. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
7. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
8. Wolfe MM. Rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:2877.
9. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-71.
10. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
11. Kim PS, Reicin AS, Villalba L, Witter J, Wolfe MM, Topol EJ. Rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:2875-8.
12. Bresalier RS, Sandier RS, Quan H, Bolognese JA, Oxenius B, Morgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
13. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial, celecoxib long-term arthritis safety study. JAMA 2000;284:1247-55.
14. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
15. EMEA. Statement on celecoxib. [Press release, Doc. Ref: EMEA/205831/2004] 2004 [cited 9 January 2005]. Available from: http://www.emea.eu.int/htms/ hotpress/h20583104.htm, accessed 4 October 2005.
16. FDA. Statement on the halting of a clinical trial of the cox-2 inhibitor Celebrex. 2004 [cited 9 January 2005]. Available from: http://www.fda.gov/bbs/ topics/news/2004/NEW01144.html, accessed 4 October 2005.
17. NIH. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial. 2004 [cited 9 January 2005]. Available from: http://www.nih.gov/news/pr/dec2004/od-20.htm, accessed 4 October 2005.
18. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-92.
19. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
20. FDA. Bextra label updated with boxed warning concerning severe skin reactions and warning regarding cardiovascular risk. [Talk Paper T04-56] 2004 [cited 9 January 2005]. Available from: http://www.fda.gov/bbs/topics/ANSWERS/ 2004/ANSO1331.html, accessed 4 October 2005.
21. Pfizer. BEXTRA: valdecoxib tablets; safety studies. 2004 [cited 9 January 2005]. Available from: http://www.pfizer.com/download/uspi_bextra.pdf, accessed 4 October 2005.
22. Ray WA, Griffin MR, Stein CM. Cardiovascular toxicity of valdecoxib. N Engl J Med 2004;351:2767.
23. FDA. Alert for healthcare professionals-valdecoxib. 2005 [cited 24 April 2005]. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/ valdecoxibHCP.pdf, accessed 4 October 2005.
24. EMEA. European Medicines Agency statement on the suspension of use of Bextra. 2005 [cited 25 April 2005]. Available from: http://www.emea.eu.int/pdfs/ human/press/pus/12163705en.pdf, accessed 4 October 2005.
25. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
26. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
27. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
28. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6.
29. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-10.
30. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002;162:1099-104.
31. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002;162:1111-15.
32. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study, Lancet 2002;359:118-23.
33. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004;177:235-43.
34. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004;164:2472-6.
35. Lecomte M, Laneuville O, Ji C, Dewitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994;269:13207-15.
36. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119(suppl):39-63S.
37. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
38. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004;127:395-402.
39. Goldstein JL, Gibofsky A, Fort JG. Incidence of endoscopie gastroduodenal ulcers in subjects on 325 mg qd of aspirin for cardiovascular prophylaxis with placebo, a COX-2 specific inhibitor, or a nonspecific NSAID; results from a randomized, double-blind, controlled trial. Arthritis Rheum 2003;46(suppl):LB14, poster 523.
40. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-16.
41. Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95:2218-24.
42. Laine L, Connors LG, Reicin A, Hawkey G, Burgos-Vargas R, Schnitzer TJ, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-92.
43. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133-41.
44. Bresalier RS, Sandler RS, Quan H, Bolognese J, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
45. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.